NCT07830719ClinicalTrials.gov
Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study of YMI024 to Assess Efficacy in Reducing Inflammatory Markers, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
En bref
The purpose of this Phase 2b study is to investigate the efficacy in reducing systemic inflammation, safety, tolerability, and dose response of five doses of YMI024, as compared to placebo in adult participants with stable coronary artery disease (CAD) and…
Phase 2180 participants recherchés23 sites5 pays
Catégories
Enregistré dans 1 registre
- ClinicalTrials.govNCT07830719Ouvrir cette fiche sur ClinicalTrials.govSynchronisé le mois dernier
Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.
Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.
Cette étude vous intéresse ?
Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 3 days after the recorded start)First posted 2026-09-21; recorded start 2026-09-18
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1147 other studies in this databaseCounted from the lead sponsor named in the record (Novartis Pharmaceuticals)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre0/8
Single site, or site count not stated
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A small study, international in scope: 180 participants (target), run at 23 sites, across 5 countries.
How this score is built
- Enrolment21/40
180 participants (target)
- Site count0/25
1 sites
- Country count0/15
Single country
- Planned duration5/10
Planned over about 13 months
- Sponsor scale10/10
Novartis Pharmaceuticals has led 1,133 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Résumé
The purpose of this Phase 2b study is to investigate the efficacy in reducing systemic inflammation, safety, tolerability, and dose response of five doses of YMI024, as compared to placebo in adult participants with stable coronary artery disease (CAD) and residual inflammatory risk defined by elevated high-sensitivity C-reactive protein (hsCRP) (≥2 mg/L)
Affections
- Coronary Artery Disease
Éligibilité
| Sexe | Tous |
|---|---|
| Âges | 18 Years – 80 Years |
| Volontaires sains | Non |
Éligibilité telle qu'elle figure dans le registre
Éligibilité en énoncés simples
Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.
Conception de l'étude
| Type d'étude | Interventionnelle |
|---|---|
| Phase | Phase 2 |
| Répartition | Randomisée |
| Modèle d'intervention | PARALLEL |
| Objectif principal | TREATMENT |
| Insu | QUADRUPLE (4) |
| Recrutement | 180 participants recherchés |
Promoteur et collaborateurs
- Novartis Pharmaceuticals Promoteur
Groupes et interventions
- YMI024 Dose 1EXPERIMENTAL
Participants receive YMI024 Dose 1 in addition to standard-of-care therapies.
- YMI024 Dose 2EXPERIMENTAL
Participants receive YMI024 Dose 2 in addition to standard-of-care therapies.
- YMI024 Dose 3EXPERIMENTAL
Participants receive YMI024 Dose 3 in addition to standard-of-care therapies.
- YMI024 Dose 4EXPERIMENTAL
Participants receive YMI024 Dose 4 in addition to standard-of-care therapies.
- YMI024 Dose 5EXPERIMENTAL
Participants receive YMI024 Dose 5 in addition to standard-of-care therapies.
- PlaceboPLACEBO_COMPARATOR
Participants receive a matching placebo in addition to standard-of-care therapies
Interventions
- Médicament Placebo
matching placebo
- Médicament YMI024
YMI024 in different doses
Critères de jugement
Critère de jugement principal
Change from baseline in log-transformed IL-6
Change from baseline in log-transformed Interleukin-6 (IL-6) to evaluate the dose-response relationship using the Multiple Comparison Procedures (MCP) component of the Multiple Comparison Procedure-Modelling (MCP-Mod) methodology
Délai Baseline and approximately 3 months
Critère de jugement secondaire
Change from baseline in log-transformed IL-6
Change from baseline in log-transformed IL-6 to characterize the dose-response relationship for YMI024 in IL-6 using the model-based (Mod) component of the MCP-Mod methodology
Délai Baseline and approximately 3 months
Critère de jugement secondaire
Change from baseline in log-transformed hsCRP
Change from baseline in log-transformed high-sensitivity C-reactive protein (hsCRP)
Délai Baseline and approximately 3 months
Critère de jugement secondaire
Responder status - hsCRP <2 mg/L
Responder status (Yes/No), defined as hsCRP \<2 mg/L
Délai Approximately 3 months
Critère de jugement secondaire
Responder status - hsCRP <1 mg/L
Responder status (Yes/No), defined as hsCRP \<1 mg/L
Délai Approximately 3 months
Critère de jugement secondaire
Number of participants with adverse events
Number of participants with adverse events, including abnormal vital signs, ECGs, and laboratory assessments
Délai Approximately 4 months
Dates
| Date de début | 18 septembre 2026 (réelle) |
|---|---|
| Achèvement principal | 15 août 2027 (estimée) |
| Achèvement | 15 août 2027 (estimée) |
| Première publication | 21 septembre 2026 (réelle) |
| Dernière mise à jour | 15 octobre 2026 |
| Résultats publiés | Non précisé dans la fiche du registre |
| Statut vérifié pour la dernière fois | octobre 2026 |
Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.
Lieux
23 sites sont en recrutement
Australia
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Adelaide | South Australia | En recrutement |
| Novartis Investigative Site | Frankston | Victoria | En recrutement |
| Novartis Investigative Site | Melbourne | Victoria | En recrutement |
| Novartis Investigative Site | Mulgrave | Victoria | En recrutement |
Germany
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Berlin | En recrutement | |
| Novartis Investigative Site | Kaiserslautern | Rhineland-Palatinate | En recrutement |
| Novartis Investigative Site | Mannheim | En recrutement | |
| Novartis Investigative Site | Pirna | En recrutement | |
| Novartis Investigative Site | Stuttgart | Baden-Wurttemberg | En recrutement |
Japan
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Kamakura | Kanagawa | En recrutement |
| Novartis Investigative Site | Kasugai | Aichi-ken | En recrutement |
| Novartis Investigative Site | Matsubara | Osaka | En recrutement |
| Novartis Investigative Site | Matsudo | Chiba | En recrutement |
United Kingdom
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | London | En recrutement |
United States
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Pharma Tex Research | Amarillo | Texas | En recrutement |
| AMR Miami | Coral Gables | Florida | En recrutement |
| Eastern Shore Research Institute | Fairhope | Alabama | En recrutement |
| G and L Research LLC | Foley | Alabama | En recrutement |
| Anderson Medical Research | Ft. Washington | Maryland | En recrutement |
| Biopharma Informatic LLC | Los Angeles | California | En recrutement |
| MD Medical Research | Oxon Hill | Maryland | En recrutement |
| Alliance for Multispecialty Research | Wichita | Kansas | En recrutement |
| Selma Medical Associates | Winchester | Virginia | En recrutement |
Documents de l'étude
Aucun document n'est lié dans cette fiche du registre.
Évolution au fil du temps
- 15 octobre 2026
Date d'achèvement avancée
Primary completion advanced 65 days
2027-10-192027-08-15
- 15 octobre 2026
Site ajouté
22 sites added (23 total)
123
- 24 septembre 2026
Statut modifié
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- 24 septembre 2026
Recrutement ouvert
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- 24 septembre 2026
Date d'achèvement reportée
Primary completion delayed 33 days
2027-09-162027-10-19
- 24 septembre 2026
Site ajouté
1 site added (1 total)
01